Guggenheim Reaffirms “Buy” Rating for Century Therapeutics (NASDAQ:IPSC)

Century Therapeutics (NASDAQ:IPSC)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a research report issued to clients and investors on Wednesday,Benzinga reports.

IPSC has been the topic of a number of other reports. Piper Sandler decreased their price objective on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a report on Monday, December 30th. Chardan Capital decreased their price objective on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Century Therapeutics in a report on Wednesday. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $10.00.

Century Therapeutics Stock Up 0.2 %

Shares of IPSC stock traded up $0.00 during trading on Wednesday, reaching $0.90. 93,253 shares of the company’s stock were exchanged, compared to its average volume of 492,434. The stock has a market capitalization of $76.44 million, a PE ratio of -0.49 and a beta of 1.76. Century Therapeutics has a twelve month low of $0.87 and a twelve month high of $5.51. The firm’s fifty day moving average price is $1.19 and its 200-day moving average price is $1.57.

Century Therapeutics (NASDAQ:IPSC) last posted its earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08. The business had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.47 million. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. During the same period in the previous year, the firm earned ($0.55) EPS. As a group, analysts anticipate that Century Therapeutics will post -1.63 EPS for the current fiscal year.

Institutional Trading of Century Therapeutics

A number of large investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its holdings in shares of Century Therapeutics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock valued at $422,000 after acquiring an additional 9,500 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Century Therapeutics during the 3rd quarter valued at about $27,000. Rhumbline Advisers increased its position in shares of Century Therapeutics by 56.0% during the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock valued at $134,000 after purchasing an additional 18,828 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Century Therapeutics by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock valued at $1,656,000 after purchasing an additional 32,614 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Century Therapeutics by 141.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock valued at $192,000 after purchasing an additional 44,155 shares during the last quarter. 50.20% of the stock is owned by hedge funds and other institutional investors.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.